// App-Quantinova.ai

516 : Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC).

Researchers

Presenter

  • Cynthia X. Ma

Principal Investigators

  • Feng Gao

  • Rachel A. Freedman

  • Mark D. Pegram

  • Kimberly Blackwell

  • Philippe L. Bedard

  • Daniel F. Hayes

  • Matthew P. Goetz

  • Polly Ann Niravath

  • Christy Ann Russell

  • Debu Tripathy

  • Melody A. Cobleigh

  • Andres Forero

  • Timothy J. Pluard

  • Carey K. Anders

  • Caroline Bumb

  • Michael Naughton

  • Hussam Al-Kateb

  • Matthew James Ellis

Medical Centers

  • Washington University School of Medicine, St. Louis, MO

  • Washington University School of Medicine, St. Louis, MO

  • Dana-Farber Cancer Institute, Boston, MA

  • Stanford School of Medicine, Stanford, CA

  • Duke University Cancer Institute, Durham, NC

  • Princess Margaret Cancer Centre, University Health Network, Division of Medical Oncology and Hematology, Toronto, ON, Canada

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • Mayo Clinic, Rochester, MN

  • Baylor College of Medicine, Houston, TX

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

  • Rush University Medical Center, Chicago, IL

  • The University of Alabama Birmingham Comprehensive Cancer Center, Birmingham, AL

  • St Luke's Cancer Institute, Kansas City, MO

  • University of North Carolina, Chapel Hill, NC

  • Washington University School of Medicine, St. Louis, MO

  • University of Arizona College of Medicine Tuscon, Tuscon, AZ

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Fulvestrant

  • Loperamide

  • Neratinib

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • II

Study Id's

  • NCT01670877HER2

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved